Disease‐modifying therapies in multiple sclerosis: A focused review of rituximab

Abstract

AbstractBackgroundTreatment for multiple sclerosis (MS), a chronic inflammatory disease of the central nervous system, has changed drastically in the last 30 years. Several different disease‐modifying therapies are now available, with off‐label use of the B‐cell‐depleting antibody rituximab becoming an increasingly popular choice, as more and more studies report on its effectiveness.ObjectivesThe objective of this study was to summarize the current state of evidence for rituximab as a treatment for relapsing‐remitting MS (RRMS).MethodsA structured literature search was conducted in PubMed, focusing on peer‐reviewed studies of adult populations with RRMS. Ongoing trials with rituximab in MS were identified through Clinicaltrials.gov and additional references were identified through review articles.FindingsDespite promising results for rituximab as a treatment of MS, the market‐authorization holder switched focus from rituximab and discontinued the industry‐sponsored trials programme. However, several observational studies, smaller clinical trials and one large investigator‐initiated randomized‐controlled trial have continued to report fewer clinical relapses, fewer contrast‐enhancing lesions on magnetic resonance imaging and better drug survival with rituximab, compared with MS‐approved alternatives.ConclusionsRituximab should be considered as both a first‐ and second‐line therapy option for most MS patients with active, non‐progressive disease. However, as an off‐label therapy for MS, regulatory approval remains a barrier for wider adoption in many countries.